Boston Partners Boosts Holdings in Chemed Corporation $CHE

Boston Partners raised its stake in shares of Chemed Corporation (NYSE:CHE) by 37.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,651 shares of the company’s stock after purchasing an additional 6,125 shares during the quarter. Boston Partners owned 0.16% of Chemed worth $11,028,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the business. Avantax Advisory Services Inc. boosted its holdings in Chemed by 6.5% in the first quarter. Avantax Advisory Services Inc. now owns 1,442 shares of the company’s stock valued at $887,000 after acquiring an additional 88 shares in the last quarter. Cetera Investment Advisers lifted its stake in Chemed by 6.2% during the 1st quarter. Cetera Investment Advisers now owns 1,715 shares of the company’s stock valued at $1,056,000 after acquiring an additional 100 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Chemed by 4.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,550 shares of the company’s stock valued at $2,184,000 after buying an additional 144 shares during the last quarter. LPL Financial LLC boosted its position in Chemed by 12.7% in the first quarter. LPL Financial LLC now owns 10,527 shares of the company’s stock worth $6,477,000 after purchasing an additional 1,185 shares during the last quarter. Finally, Mackenzie Financial Corp increased its holdings in Chemed by 1.4% during the first quarter. Mackenzie Financial Corp now owns 4,694 shares of the company’s stock valued at $2,888,000 after buying an additional 65 shares during the last quarter. 95.85% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Bank of America cut their price objective on shares of Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, October 8th. Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and raised their target price for the company from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada dropped their price target on Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a research note on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $574.25.

Insider Activity

In other news, CEO Kevin J. Mcnamara sold 3,000 shares of the firm’s stock in a transaction on Friday, September 26th. The shares were sold at an average price of $461.28, for a total value of $1,383,840.00. Following the completion of the sale, the chief executive officer owned 96,197 shares in the company, valued at approximately $44,373,752.16. This trade represents a 3.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patrick P. Grace sold 150 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the transaction, the director owned 3,397 shares of the company’s stock, valued at $1,574,135.83. This represents a 4.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 5,150 shares of company stock worth $2,328,449 in the last 90 days. 3.29% of the stock is currently owned by insiders.

Chemed Trading Down 0.5%

Chemed stock opened at $439.19 on Friday. The stock has a market cap of $6.22 billion, a P/E ratio of 23.23, a PEG ratio of 2.69 and a beta of 0.43. Chemed Corporation has a 12-month low of $408.42 and a 12-month high of $623.60. The company has a 50-day moving average price of $440.55 and a 200 day moving average price of $474.60.

Chemed (NYSE:CHE) last posted its earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing the consensus estimate of $5.39 by ($0.12). Chemed had a net margin of 11.02% and a return on equity of 25.89%. The company had revenue of $624.90 million during the quarter, compared to analyst estimates of $626.04 million. During the same quarter last year, the business posted $5.64 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, analysts forecast that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Monday, November 17th will be given a dividend of $0.60 per share. The ex-dividend date is Monday, November 17th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. Chemed’s dividend payout ratio (DPR) is 12.69%.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.